Rajat Bannerji

May 4, 2024 | onlinelibrary.wiley.com | Sam Yuen |Tycel J. Phillips |Rajat Bannerji |Paula Marlton

1 INTRODUCTION Advanced-stage follicular lymphoma (FL) has recurrent relapses and is incurable with standard treatments.1 Diffuse large B-cell lymphoma (DLBCL), although potentially curable with initial anthracycline-based chemoimmunotherapy, presents as relapsed/refractory (R/R) disease in 40% of patients.1 Therefore, novel treatment options with improved efficacy and safety are needed for these B-cell non-Hodgkin lymphoma (NHL) subtypes.